Ibrolipim

Research use only, not for human use.

Ibrolipim attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway.

Ibrolipim attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway.

Western Blot Analysis Cell Line:THP-1 macrophage-derived foam cells Concentration:0.5 μM, 5 μM, 10 μM Incubation Time:0 hour, 6 hours, 12 hours, 24 hours Result:Increased ABCA1 and ABCG1 translational levels in a dose-dependent and time-dependent manner.RT-PCR Cell Line:THP-1 macrophage-derived foam cells Concentration:0.5 μM, 5 μM, 10 μM Incubation Time:0 hour, 6 hours, 12 hours, 24 hours Result:Increased ABCA1 and ABCG1 expression at the transcriptional levels in a dose-dependent and time-dependent manner.

Animal Model:Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment Dosage:100 mg/kg Administration:Oral administration; daily; for 8 weeks Result:Decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy.

NO-1886

Others

Other Targets

Lipoprotein lipase (LPL)

——

——

133208-93-2

451.25

Br1C19H20N2O4P1

>98% (HPLC)

DMSO:125 mg/mL (277.01 mM; Need ultrasonic)

CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC

Diethyl (4-((4-bromo-2-cyanophenyl)carbamoyl)benzyl)phosphonate

(-20℃)

With Ice Pack

≥ 2 years